阿可替尼联合苯达莫司汀-利妥昔单抗治疗初治套细胞淋巴瘤
这项随机对照研究纳入598例65岁及以上初治套细胞淋巴瘤患者,比较阿可替尼或安慰剂联合苯达莫司汀-利妥昔单抗及利妥昔单抗维持治疗。中位随访49.8个月,阿可替尼组中位无进展生存期为66.4个月,安慰剂组为49.6个月(HR 0.73,95%CI 0.57-0.94,P=0.0160),总生存无显著差异(HR 0.86,95%CI 0.65-1.13,P=0.27)。
要点
- 阿可替尼联合苯达莫司汀-利妥昔单抗较安慰剂联合方案显著改善无进展生存期(HR 0.73)。
- 总生存无显著差异(HR 0.86,95%CI 0.65-1.13,P=0.27)。
- 两组≥3级不良事件发生率分别为88.9%和88.2%,毒性可管理。
核心结论
- 阿可替尼联合苯达莫司汀-利妥昔单抗显著改善初治套细胞淋巴瘤患者的无进展生存期,且临床获益伴随可管理的毒性。
研究设计与样本
- 随机对照试验,纳入598例65岁及以上既往未经治疗的套细胞淋巴瘤患者,随机分配至阿可替尼组(299例)或安慰剂组(299例)。
- 阿可替尼100 mg每日两次或安慰剂持续给药至疾病进展或不可耐受毒性,联合6个周期苯达莫司汀(90 mg/m2,第1、2天每日一次)和利妥昔单抗(375 mg/m2单次给药,第1天),随后应答患者接受利妥昔单抗维持治疗2年。
- 允许疾病进展时交叉至阿可替尼;主要终点为独立评审委员会评估的无进展生存期,总缓解率和总生存为次要终点。
主要发现
- 中位随访49.8个月(反向Kaplan-Meier法),阿可替尼组中位无进展生存期为66.4个月,安慰剂组为49.6个月(HR 0.73,95%CI 0.57-0.94,P=0.0160)。
- 所有亚组均观察到获益,包括具有高危特征的患者。
- 阿可替尼组和安慰剂组的总缓解率分别为91.0%和88.0%,完全缓解率分别为66.6%和53.5%。
- 总生存无显著差异(HR 0.86,95%CI 0.65-1.13,P=0.27)。
- 阿可替尼组和安慰剂组≥3级不良事件发生率分别为88.9%和88.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS), but without improvement in overall survival (OS), likely because of toxicity. Acalabrutinib was shown to be efficacious and less toxic than ibrutinib in a head-to-head trial in chronic lymphocytic leukemia and therefore might lead to better outcomes in MCL. METHODS: Patients 65 years and older with previously untreated MCL received acalabrutinib (100 mg twice daily) or placebo (until disease progression or unacceptable toxicity), plus six cycles of bendamustine (90 mg/m2 once daily; days 1 and 2) and rituximab (375 mg/m2 as a single dose; day 1) followed by rituximab maintenance in responding patients for 2 years. Crossover to acalabrutinib at disease progression was permitted. The primary end point was PFS per the independent review committee; overall response rate and OS were secondary end points. RESULTS: In total, 598 patients were randomly assigned, with 299 in each arm. At a median follow-up of 49.8 months using the reverse Kaplan-Meier method, the median PFS was 66.4 months in the acalabrutinib arm and 49.6 months in the placebo arm (hazard ratio [HR], 0.73 [95% CI, 0.57 to 0.94]; P = .0160). Benefit was seen across all subgroups, including those with high-risk features. Overall response/complete response rates were 91.0%/66.6% and 88.0%/53.5% in the acalabrutinib and placebo arms, respectively. OS was not significantly different (HR, 0.86 [95% CI, 0.65 to 1.13]; P = .27). Grade 3 or greater adverse events were reported in 88.9% and 88.2% in the acalabrutinib and placebo arms, respectively. CONCLUSION: The combination of acalabrutinib with bendamustine-rituximab significantly improved PFS. Clinical benefit of acalabrutinib with bendamustine-rituximab was achieved with manageable toxicity.
引用
- Wang M, Salek D, Belada D, et al. Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. J Clin Oncol. 2025. PMID: 40311141. doi:10.1200/JCO-25-00690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。